RBC Capital Gives a Buy Rating to Shire

By Carrie Williams

In a report released today, Nicholas Keher from RBC Capital assigned a Buy rating to Shire (NASDAQ: SHPG), with a price target of $213. The company’s shares opened today at $152.19.

According to TipRanks.com, Keher is a 2-star analyst with an average return of 0.4% and a 40.0% success rate. Keher covers the Healthcare sector, focusing on stocks such as Novelion Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.

Currently, the analyst consensus on Shire is Strong Buy and the average price target is $228.25, representing a 50.0% upside.

In a report issued on October 3, Cantor Fitzgerald also assigned a Buy rating to the stock with a $222 price target.

Shire’s market cap is currently $45.8B and has a P/E ratio of 70.42. The company has a book value ratio of 1.4657.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Shire Plc is a biopharmaceutical company. The company focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.